SCHEDULE: Invesco Ltd. Reports 6.2% Stake in Charles River Labs

Invesco Ltd. has disclosed beneficial ownership of 6.2% of Charles River Laboratories International Inc.'s common stock as of June 30, 2026.

Summary

• Invesco Ltd. has filed a Schedule 13G, indicating its beneficial ownership of 2,984,785 shares of Charles River Laboratories International Inc. common stock.
• This ownership represents 6.2% of the class of securities.
• The filing is made by Invesco Ltd. as a parent holding company for its investment advisers.
• The shares are held by clients of Invesco Ltd., who have the right to receive dividends and direct the sale of the securities.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership percentage without indicating a change in investment strategy or significant company performance.

Positives

• Invesco Ltd. maintains a significant stake, suggesting continued confidence in Charles River Laboratories.
• The clear disclosure of ownership percentage (6.2%) provides transparency for investors.

Negatives

• The filing does not provide specific details on the investment strategy or rationale behind the ownership level.
• No forward-looking statements or performance indicators are included in this type of filing.

Risks

• Potential for future changes in Invesco's stake, which could impact share price if significant buying or selling occurs.
• Market volatility affecting the value of the 2,984,785 shares held.

Future Outlook

This filing is a report of beneficial ownership and does not contain forward-looking statements or specific future guidance from Invesco Ltd. regarding its investment in Charles River Laboratories.

Management Comments

• "Invesco Ltd., in its capacity as a parent holding company to its investment advisers, may be deemed to beneficially own 2,984,785 shares of the Issuer which are held of record by clients of Invesco Ltd."
• "No one person has greater than 5% economic ownership in the securities listed above."
• "As holders of record, the relevant clients of Invesco Ltd. have the right to receive or the power to direct the receipt of dividends from, and proceeds from the sale of, the securities listed above."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors like Invesco Ltd. when their beneficial ownership crosses certain thresholds. This filing indicates Invesco's role as a significant, but not controlling, shareholder in the contract research organization (CRO) sector.

Stakeholder Impact

• Shareholders: Provides transparency on a significant institutional investor's stake, potentially influencing market perception.
• Management of Charles River Laboratories: May be aware of Invesco's significant holding and its implications for corporate governance and strategic decisions.
• Regulators: Ensures compliance with SEC reporting requirements for beneficial ownership.

Next Steps

• Invesco Ltd. will continue to hold its beneficial ownership in Charles River Laboratories International Inc.
• Future filings will be made if Invesco's beneficial ownership changes significantly.

Key Dates

Keywords

beneficial ownership, Schedule 13G, Invesco Ltd., Charles River Laboratories, investment management, institutional investor, common stock